{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:02:28Z","timestamp":1769205748818,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2018_A84"],"award-info":[{"award-number":["2018_A84"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00428-022-03369-6","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T05:02:31Z","timestamp":1656738151000},"page":"443-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Deglycosylation of pathological specimens alters performance of diagnostic PDL1 antibodies"],"prefix":"10.1007","volume":"481","author":[{"given":"Franz F.","family":"Dressler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devang S.","family":"Dabadghao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luise","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Perner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Idel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julika","family":"Ribbat-Idel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"issue":"1","key":"3369_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12885-018-5259-8","volume":"19","author":"Q An","year":"2019","unstructured":"An Q, Liu Z (2019) Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis. BMC Cancer 19(1):43","journal-title":"BMC Cancer"},{"issue":"1079","key":"3369_CR2","doi-asserted-by":"publisher","first-page":"20170442","DOI":"10.1259\/bjr.20170442","volume":"90","author":"JK Jacinto","year":"2017","unstructured":"Jacinto JK et al (2017) The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. Br J Radiol 90(1079):20170442","journal-title":"Br J Radiol"},{"issue":"4","key":"3369_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/0002-9610(83)90247-7","volume":"146","author":"DL Larson","year":"1983","unstructured":"Larson DL et al (1983) Major complications of radiotherapy in cancer of the oral cavity and oropharynx. The American Journal of Surgery 146(4):531\u2013536","journal-title":"The American Journal of Surgery"},{"issue":"10167","key":"3369_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet 393(10167):156\u2013167","journal-title":"The Lancet"},{"issue":"11","key":"3369_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41571-019-0227-z","volume":"16","author":"JD Cramer","year":"2019","unstructured":"Cramer JD et al (2019) The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol 16(11):669\u2013683","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"3369_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1634\/theoncologist.2016-0496","volume":"22","author":"E Larkins","year":"2017","unstructured":"Larkins E et al (2017) FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist 22(7):873\u2013878","journal-title":"Oncologist"},{"key":"3369_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","volume":"81","author":"RL Ferris","year":"2018","unstructured":"Ferris RL et al (2018) Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81:45\u201351","journal-title":"Oral Oncol"},{"key":"3369_CR8","doi-asserted-by":"publisher","first-page":"640515","DOI":"10.3389\/fmed.2021.640515","volume":"8","author":"J Ribbat-Idel","year":"2021","unstructured":"Ribbat-Idel J et al (2021) Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma. Front Med (Lausanne) 8:640515","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3369_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-016-0334-6","volume":"9","author":"WL Ho","year":"2016","unstructured":"Ho WL et al (2016) Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma. J Hematol Oncol 9(1):100","journal-title":"J Hematol Oncol"},{"key":"3369_CR10","doi-asserted-by":"crossref","unstructured":"Santarpia M, et al. 2020 Non-small-cell lung cancer signaling pathways, metabolism, and PD-1\/PD-L1 antibodies. Cancers (Basel) 12(6)","DOI":"10.3390\/cancers12061475"},{"issue":"9","key":"3369_CR11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jtho.2018.04.030","volume":"13","author":"J Codony-Servat","year":"2018","unstructured":"Codony-Servat J et al (2018) Anti-epidermal growth factor vaccine antibodies enhance the efficacy of tyrosine kinase inhibitors and delay the emergence of resistance in EGFR mutant lung cancer cells. J Thorac Oncol 13(9):1324\u20131337","journal-title":"J Thorac Oncol"},{"issue":"22","key":"3369_CR12","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","volume":"78","author":"JM Hsu","year":"2018","unstructured":"Hsu JM et al (2018) Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res 78(22):6349\u20136353","journal-title":"Cancer Res"},{"issue":"3","key":"3369_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10555-017-9687-8","volume":"36","author":"MJ Xu","year":"2017","unstructured":"Xu MJ, Johnson DE, Grandis JR (2017) EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev 36(3):463\u2013473","journal-title":"Cancer Metastasis Rev"},{"key":"3369_CR14","doi-asserted-by":"crossref","unstructured":"Lee HH, et al. 2018 Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy. Cancer Cell","DOI":"10.1016\/j.ccell.2019.06.008"},{"key":"3369_CR15","doi-asserted-by":"crossref","unstructured":"Klapper L, et al. (2020) NR2F6 as a prognostic biomarker in HNSCC. Int J Mol Sci 21(15)","DOI":"10.3390\/ijms21155527"},{"issue":"8","key":"3369_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/modpathol.2010.87","volume":"23","author":"VJ Scheble","year":"2010","unstructured":"Scheble VJ et al (2010) ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23(8):1061\u20131067","journal-title":"Mod Pathol"},{"issue":"2","key":"3369_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/pcan.2011.67","volume":"15","author":"M Braun","year":"2012","unstructured":"Braun M et al (2012) ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer\u2013a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis 15(2):165\u2013169","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"3369_CR18","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P et al (2017) QuPath: Open source software for digital pathology image analysis. Sci Rep 7(1):16878","journal-title":"Sci Rep"},{"issue":"11","key":"3369_CR19","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/sim.6082","volume":"33","author":"JJ Goeman","year":"2014","unstructured":"Goeman JJ, Solari A (2014) Multiple hypothesis testing in genomics. Stat Med 33(11):1946\u20131978","journal-title":"Stat Med"},{"issue":"9470","key":"3369_CR20","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(05)66461-6","volume":"365","author":"KF Schulz","year":"2005","unstructured":"Schulz KF, Grimes DA (2005) Multiplicity in randomised trials I: endpoints and treatments. The Lancet 365(9470):1591\u20131595","journal-title":"The Lancet"},{"issue":"1","key":"3369_CR21","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1038\/s41598-017-04844-w","volume":"7","author":"X Cai","year":"2017","unstructured":"Cai X et al (2017) The importance of N-glycosylation on beta3 integrin ligand binding and conformational regulation. Sci Rep 7(1):4656","journal-title":"Sci Rep"},{"issue":"2","key":"3369_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/glycob\/cwz080","volume":"30","author":"WS York","year":"2020","unstructured":"York WS et al (2020) GlyGen: computational and informatics resources for glycoscience. Glycobiology 30(2):72\u201373","journal-title":"Glycobiology"},{"issue":"D1","key":"3369_CR23","doi-asserted-by":"publisher","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","volume":"49","author":"C UniProt","year":"2021","unstructured":"UniProt C (2021) UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res 49(D1):D480\u2013D489","journal-title":"Nucleic Acids Res"},{"key":"3369_CR24","unstructured":"Abcam. Antibody ab51880 supplier web page. 12.12.2021]; Available from: https:\/\/www.abcam.com\/pd-l1-antibody-ab58810.html."},{"issue":"4","key":"3369_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2559.2006.02513.x","volume":"49","author":"CR Taylor","year":"2006","unstructured":"Taylor CR, Levenson RM (2006) Quantification of immunohistochemistry\u2013issues concerning methods, utility and semiquantitative assessment II. Histopathology 49(4):411\u2013424","journal-title":"Histopathology"},{"issue":"4","key":"3369_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41379-019-0372-z","volume":"33","author":"NL Lawson","year":"2020","unstructured":"Lawson NL et al (2020) Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Mod Pathol 33(4):518\u2013530","journal-title":"Mod Pathol"},{"issue":"3","key":"3369_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/biomet\/62.3.531","volume":"62","author":"SJ Devlin","year":"1975","unstructured":"Devlin SJ, Gnanadesikan R, Kettenring JR (1975) Robust estimation and outlier detection with correlation coefficients. Biometrika 62(3):531\u2013545","journal-title":"Biometrika"},{"issue":"10","key":"3369_CR28","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1074\/mcp.RA117.000037","volume":"16","author":"CA Morales-Betanzos","year":"2017","unstructured":"Morales-Betanzos CA et al (2017) Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol Cell Proteomics 16(10):1705\u20131717","journal-title":"Mol Cell Proteomics"}],"updated-by":[{"DOI":"10.1007\/s00428-022-03381-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000}}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03369-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03369-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03369-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T17:07:21Z","timestamp":1663607241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03369-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3369"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03369-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00428-022-03381-w","asserted-by":"object"}]},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00428-022-03381-w","URL":"https:\/\/doi.org\/10.1007\/s00428-022-03381-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}